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Amino-acid transporters in T-cell activation and
differentiation
Wenkai Ren1,2, Gang Liu1, Jie Yin1, Bie Tan*,1, Guoyao Wu3, Fuller W Bazer3, Yuanyi Peng4 and Yulong Yin*,1
T-cell-mediated immune responses aim to protect mammals against cancers and infections, and are also involved in the
pathogenesis of various inflammatory or autoimmune diseases. Cellular uptake and the utilization of nutrients is closely related to
the T-cell fate decision and function. Research in this area has yielded surprising findings in the importance of amino-acid
transporters for T-cell development, homeostasis, activation, differentiation and memory. In this review, we present current
information on amino-acid transporters, such as LAT1 (L-leucine transporter), ASCT2 (L-glutamine transporter) and GAT-1
(γ-aminobutyric acid transporter-1), which are critically important for mediating peripheral naive T-cell homeostasis, activation and
differentiation, especially for Th1 and Th17 cells, and even memory T cells. Mechanically, the influence of amino-acid transporters
on T-cell fate decision may largely depend on the mechanistic target of rapamycin complex 1 (mTORC1) signaling. These
discoveries remarkably demonstrate the role of amino-acid transporters in T-cell fate determination, and strongly indicate that
manipulation of the amino-acid transporter-mTORC1 axis could ameliorate many inflammatory or autoimmune diseases
associated with T-cell-based immune responses.
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Facts
(1) The cellular metabolic pathways are associated with the
shaping T-cell development, homeostasis, activation,
differentiation and even memory.
(2) AA transporters are critical for T-cell fate decision.
(3) AA transporters, such as LAT1, ASCT2, and GAT-1, have
important roles in peripheral naive T-cell homeostasis,
T-cell activation and differentiation, especially for Th1 and
Th17 cells, and T-cell memory.
(4) The influence of AA transporters on T-cell fate decision
may largely depend on mTORC1 signaling.
Open Questions
(1) Besides LAT1, ASCT2, and GAT-1, whether other AA
transporters are also expressed in T cells and function in
T-cell fate decision, and how do they affect the T-cell fate
decision?
(2) In addition to mTORC1 signaling, do AA transporters
affect T-cell fate decision through other molecular
mechanisms?
(3) Do AA transporters also affect unconventional T cells,
including CD1-restricted T cells, MR1-restricted mucosal-
associated invariant T cells, MHC class Ib-reactive T cells
and γδ T cells?
T-cell-mediated immune responses are necessary to effi-
ciently protect mammals against infections. To protect the host
from infection, naive T cells need to go through the following
phases: (a) a beginning phase with massive clonal expansion
and differentiation of T cells; (b) a second phase, including the
migration of T cells to relevant tissues, synthesis of cytokines
and effector molecules, as well as the clearance of most
effector cells; and (c) a final phase with the generation of
memory T cells. This process imposes considerable demands
for energy and biosynthetic precursors.1 The uptake and utili-
zation of nutrients highly affects T-cell development, homeo-
stasis, activation, differentiation and memory.1–5 T cells in
each stage or even distinct T-cell subsets within a similar stage
display unique metabolic programs (Figure 1). For example,
naive T cells are quiescent to avoid nonspecific or excess
immune reactions, thus their intracellular metabolism is largely
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dependent on the tricarboxylic acid (TCA) cycle and oxidative
phosphorylation (OXPHOS) for the generation of adenosine
triphosphate (ATP).4 Upon activation, T cells rapidly proliferate
and differentiate, and produce various cytokines, all of which
require more energy substrates.6 Activated T cells fulfill these
demands through swift metabolic changes that increase
glycolysis, glutaminolysis and fatty acid synthesis.4 Also,
human T-regulatory cells mainly use fatty acid oxidation (FAO)
when proliferating in vitro, whereas the proliferation of human
T conventional cells mainly depends on the metabolism of
glucose.7 Thus, there is increasing interest in regulating T-cell
fate decision by modulating the abundance of nutrients in
cells, expression of nutrient transporters and activation of
metabolic pathways, especially for those of glucose and fatty
acid.1,2,8 Amino acids (AA) or AA transporters are also crucial
in T-cell-mediated immunity.9–11 For example, activated T cells
use glutamine to fuel metabolism, as a nitrogen source and
as an anapleurotic substrate.12 This review focuses on our
current understanding of AA transporters and their signifi-
cance in the development, differentiation, homeostasis,
activation and memory processes of T cells.
Expression of AA transporters in T cells
Based on their substrate specificity, transport mechanism and
regulatory properties,13,14 AA transporters can be classified
as: (1) sodium-dependent neutral AA transporters, including
system A [SNAT-1 (Slc38a1), SNAT-2 (Slc38a2), SNAT4
(Slc38a4)], ASC [ASCT1 (Slc1a4), ASCT2 (Slc1a5)], BETA
[GAT-1 (Slc6a1), GAT-2 (Slc6a13), GAT3 (Slc6a11), BGT1
(Slc6a12), TAUT (Slc6a6)], Gly [GLYT1 (Slc6a9), GLYT2
(Slc6a5)], N [SNAT3 (Slc38a3), SNAT5 (Slc38a5)] and PRQT
[PROT (Slc6a7)]; (2) sodium-independent neutral AA trans-
porters, including system asc* [Asc (Slc7a10)], imino
[PAT1/LYAAT1 (Slc36a1), PAT2/LYAAT2 (Slc36a2)], L* [LAT1
(Slc7a5), LAT2 (Slc7a8)] and T [TAT1 (Slc16a10)]; (3) sodium-
dependent anionic AA transporters-system X−AG [EAAT1
(Slc1a3), EAAT2 (Slc1a2), EAAT3 (Slc1a1), EAAT4 (Slc1a6),
EAAT5 (Slc1a7)]; (4) sodium-independent anionic AA trans-
porters system x− C* [xCT (Slc7a11)]; (5) sodium-dependent
cationic AA transporters, including system B0,+ [ATB(0,+)
(Slc6a14)] and y+L* [y+LAT1 (Slc7a7), y+LAT2 (Slc7a6)]; and
(6) sodium-independent cationic AA transporters, including
system b0,+** [b(0,+)AT (Slc7a9)] and y+ [Cat-1 (Slc7a1), Cat-2
(Slc7a2), Cat-3 (Slc7a3), Cat-4 (Slc7a4)]. T cells express
various AA transporters (Figure 2). For example, fetal T cells
express SNAT-1 and SNAT-2 mRNAs.15 T cells express
various numbers of the system BETA family, including
GAT-1,9,16,17 GAT-2,17 BGT118 and TAUT.19 Other AA trans-
porters have also been reported in T cells, such as ASCT2,10
LAT120 and Cat-1.21
Collectively, although a full expression profile of AA transpor-
ters in T cells is missing, current evidence shows that T cells
express various types of AA transporters, and AA transporters
may affect the T-cell fate decision, including development,
homeostasis, activation/differentiation and memory.
AA transporters and intrathymic development of T cells
Major events for the development of T cells in the thymus are
well established.5,22–24 Conventional T cells (T-cell receptor
(TCR) αβ) experience sequential developmental stages before
Figure 1 Dominant metabolic pathways in different stages of T cells. Although T cells at all stages can use glucose, AAs and fatty acids, the main metabolic pathways differ
depending on the stage of the T cells. Glycolysis is important for T-cell development in the thymus, while most energy for naive T cells is produced in the mitochondria through the
fermentation of acetyl-coenzyme A (CoA) in the TCA cycle and OXPHOS. Upon activation, T cells rapidly and massively upregulate the glycolytic, glutaminolytic and pentose
phosphate pathways for the production of energy and synthesis of biomass. Also, activated T cells switch from lipid metabolism via β-oxidation to fatty acid synthesis. For T-cell
differentiation, effector T cells use energy from glucose through glycolysis, and AA through glutaminolysis, whereas regulatory T cells use energy from FAO. Memory T cells
mainly use β-oxidation of fatty acids to meet their energy needs
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the emergence of naive resting T cells, including CD4−CD8−
double-negative (DN) thymocytes, CD4+CD8+ double-positive
(DP) thymocytes and CD4+ or CD8+ single-positive (SP)
thymocytes (Figure 3). CD4−CD8− DN thymocytes are
further classified into four sub-populations (DN1–4) based
on their expression of CD25 and CD44: DN1 (CD25−CD44+),
DN2 (CD25+CD44+), DN3 (CD25+CD44−) and DN4 (CD25−
CD44−) (Figure 3).
In the thymus, the development of T cells is highly depen-
dent on the cellular metabolism. Alterations in metabolism-
related signals significantly effect T-cell development, such as
phosphatidylinositol 3-kinase-Akt, AMP-activated protein
kinase and Notch signaling.3 However, the AA-tuned mechan-
istic target of rapamycin complex 1 (mTORC1) has limited
influence on T-cell development in the thymus. Mice with Tsc1
(an inhibitor of mTORC1) deletion in T cells have similar
numbers of total thymocytes, DN, DP, CD4+ SP and CD8+ SP
subsets, as well as a comparable expression of thymocyte
maturation markers, including CD62L, CD69 and CD24,
compared to wild-type (WT) mice.25 Similarly, another
independent study has found that Tsc1 deletion in the
T cells of mouse has little effect on the total number of thymic
cells and the percentages of thymocyte subsets, including DN,
DP, CD4+ SP and CD8+ SP cells in the thymus.26 Mice with
Raptor (an obligate adaptor for mTORC1) deficiency in T cells
have similar percentages and numbers of total thymocytes,
DN, DP, CD4+ SP and CD8+ SP subsets, when compared with
WT mice.27 Interestingly, although mice with T-cell-specific
Raptor deficiency show little effect on T-cell development,
rapamycin (an inhibitor of mTORC1) treatment or Raptor
deficiency in all tissues of mice induces apparent atrophy of
the thymus and inhibits T-cell development.28 Rapamycin
significantly decreases the percentage of DP cells, but
increases the percentage of DN3 cells, suggesting that
rapamycin largely blocks DN3 to DP differentiation.28 Mice
Figure 2 Expression of AA transporters in T cells. Current evidence shows that
T cells express SNAT1 (Slc38a1), SNAT2 (Slc38a2), GAT-1 (Slc6a1), GAT-2
(Slc6a13), BGT1 (Slc6a12), TAUT (Slc6a6), ASCT1 (Slc1a4), ASCT2 (Slc1a5), LAT1
(Slc7a5), LAT2 (Slc7a8) and Cat-1 (Slc7a1). Other means that the expression of more
AA transporters in T cells needs further investigation
Figure 3 Roles of AA transporters in T-cell fate. The influences of AA transporters on T-cell development, homeostasis, activation/differentiation and memory processes are
illustrated here. AA transporters may be needed for the homeostasis of resting T cells and T-cell memory (dashed arrows), whereas AA transporters have critical importance in
the activation and differentiation of T cells (black arrows). Conventional T cells experience sequential developmental stages before the emergence of naive resting T cells,
including CD4−CD8− DN thymocytes, CD4+CD8+ DP thymocytes and CD4+ or CD8+ SP thymocytes. CD4−CD8− DN thymocytes can be further classified into four sub-
populations (DN1–4) based on the expression of CD25 and CD44: DN1 (CD25−CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44−) and DN4 (CD25−CD44−). A: LAT1 and
ASCT2 promote T-cell activation, whereas GATs inhibit T-cell activation. B: LAT1 and ASCT2 are positively associated with the differentiation of T-helper type 1 and 17 (Th1 and
Th17) cells, whereas GAT-1 is negatively associated with differentiation of Th1 and Th17 cells
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with Raptor deficiency in all tissues show a reduction in the
absolute numbers of DN2 andDN3 cells, but an increase in the
proportion of DN1 cells, indicating that Raptor has an
important role in the development of early T-cell progenitors,
particularly at the DN2 stage.28 Thus, mTORC1 signaling may
regulate early T-cell development, but may not be critically
involved in the late development of T cells.
CD98 (Slc3a2) forms complexeswith either Slc7a5, Slc7a8,
Slc7a7 or Slc7a6 to form system L* and system y+L AA
transporters, which transport leucine and large neutral AA.29
Early observations that DN cells express CD9830 indicated
that some AA transporters might have an important influence
on the development of T cells in the thymus. Selective deletion
of CD98 in mouse T cells markedly reduces the clonal
expansion of T cells,31 and mice with CD98 deficiency in
T cells can accept a full major histocompatibility complex-
mismatched cardiac allograft.32 Further research has indi-
cated that CD98 regulates T cells by amplifying integrin
signaling, but not because it forms complexes with some AA
transporter light chains.31Slc7a5fl/flCD4-Cremice, which have
deletion of the Slc7a5 in DP thymocytes and all subsequent
T-cell populations, exhibit normal numbers and frequencies of
conventional αβ T cells in the thymus.11 The Slc7a5fl/flVav-Cre
mice with deletion of Slc7a5 in hematopoietic progenitors in
bone marrow have normal thymocyte numbers and distribu-
tion of CD4−CD8−DN, CD4+CD8+ DP, CD4+ SPand CD8+ SP
subsets.11 Deletion of the Slc1a5 in mice shows normal
thymocyte development compared with WT mice, as revealed
by the comparable frequencies of thymocyte sub-populations,
including CD4−CD8− DN, CD4+CD8+ DP, CD4+ SP, CD8+ SP
subsets, and similar numbers of total thymocytes in the
Slc1a5+/+ and Slc1a5–/– mice.10 The γ-aminobutyric acid
(GABA) transporter-1 (GAT-1) also has a limited role in T-cell
development in the thymus based on evidence that Slc6a1−/−
mice9 exhibit similar percentages and numbers of total
thymocytes, of CD4−CD8− DN and CD4+CD8+ DP subsets
and CD4+ SP and CD8+ SP subsets, with their controls.
Although understanding of the roles of other AA transporters
in T-cell development in the thymus requires further investiga-
tion, these present compelling studies indicate a limited
importance of AA transporters in T-cell development in the
thymus.
AA transporters and naive T-cell homeostasis
Resting naive T cells are characterized by their small cell size
and continuous migration through the secondary lymphoid
tissues for immune surveillance. To promote homeostatic
growth and survival, naive T cells require ATP generated from
the TCA cycle and OXPHOS (Figure 1).3,33 Thus, these cells
can use a variety of nutrients to meet metabolic demands,
including glucose through glycolysis, AA through glutamine
oxidation and lipids through fatty acid β-oxidation.4 Besides
the engagement of TCRs by the self-peptide-MHC complex,
the interaction between interleukin-7 (IL-7) and IL-7R is of
critical importance to naive T-cell homeostasis, proliferation
and prolonged survival.34,35 Although AAs are not required for
IL-7-induced survival of naive CD8+ T cells, AAs are essential
for themaintenance of naiveCD8+ T-cell size and IL-7-induced
growth.36 CD8+ T cells express mRNAs of several AA
transporters, including Slc1a4, Slc1a5, Slc7a5 and Slc7a6,
and IL-7 stimulation increases the transcription of Slc1a4,
Slc1a5 and Slc7a5 in CD8+ T cells.36 Although the CD4+ :
CD8+ ratios in the spleen, peripheral blood and lymph nodes,
and T-cell percentages in peripheral blood and lymph nodes
are similar between WT mice and mice with an mTORC1
deficiency in T cells,37 the mTORC1 pathway is a critical
factor for the maintenance of quiescence and homeostasis of
peripheral T cells because Tsc− /− T cells,25,38 Pten−/−
(phosphatase and tensin homolog, an inhibitor of mTORC1
signaling) T cells39 and Lkb1− /− (liver kinase B1, an inhibitor of
mTORC1 signaling) T cells40,41 lose quiescence and sponta-
neous entry into the cell cycle and are sensitive to undergoing
apoptosis, compared with WT controls. These evidences
indicate that AA transporters may have critical roles in the
homeostasis of peripheral naive T cells.
Mice with a single Slc7a5 allele deletion have normal
peripheral lymphocyte sub-populations.11 Slc7a5fl/flCD4-Cre
mice show little change in the numbers and frequencies of naive
CD4+ and CD8+ T-cell subsets in the spleen and lymph nodes,
and little alteration in the numbers and frequencies of peripheral
T-lymphocyte sub-populations.11 At young ages (6–7 weeks),
Slc1a5–/– mice have similar numbers of T cells, naive CD4+
T cells and naive CD8+ T cells in the spleen, compared to the
Slc1a5+/+ mice.10 However, older Slc1a5–/– mice (5–6 months)
have a reduced percentage and number of CD4+ T cells, while
there is an increased frequency of the CD44loCD62Lhi-naive
CD4+ T cells compared with Slc1a5+/+ mice.10 These results
suggest that AA transporters have few roles in maintaining
peripheral naive T-cell homeostasis in young mice, but may
affect naive T-cell homeostasis in older mice. A deficiency of
GAT-1 in a mouse does not affect naive T-cell homeostasis
because Slc6a1−/− mice have similar numbers of CD4+ cells,
CD8+ cells and similar ratios of T cells/B cells and CD4+ cells/
CD8+ cells in the spleen as for WT mice.9
Collectively, these studies suggest that AA transporters
have little effect on the homeostasis of peripheral naive T cells,
but may have some critical roles in special situations such as
with aged mice.
AA transporters and activation of T cells
Upon sensing a specific antigen by TCR on quiescent T cells,
T cells are activated. Activated T cells proliferate rapidly and
exert effector functions, such as cytokine production, which
are largely dependent on the cellular metabolism to synthe-
size lipids, nucleic acids and proteins. Thus, once activated,
T cells trigger a considerable metabolic switch, resulting in an
increase in activities of the glycolytic pathway, pentose
phosphate pathway and glutaminolysis, while decreasing
FAO (Figure 1).3,4,42 Because of the increase in metabolic
requirement, activated T cells need to consume large amounts
of intracellular materials such as AAs and glucose; thus; they
boost the rate of uptake of those nutrients by increasing the
expression of transporters for glucose and AAs.
L-Leucine transportation by LAT1 increases during T-cell
activation by PMA and ionomycin, compared with quiescent
T cells.43 Also, the abundance of CD98 and LAT1 hetero-
complex and the expression of LAT1 and CD98 mRNAs
increases in activated T cells, compared with quiescent T
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cells.43 Although naive human primary T cells express an
almost undetectable amount of LAT1 protein, activation of
human primary T cells by anti-CD3 and anti-CD28 Abs
markedly induces LAT1 abundance associated with activator
protein-1 (AP-1) and nuclear factor-κB (NF-κB) signaling,
which suggests that LAT1 is required for the full activation of
T cells.20 JPH203 (a LAT1-specific inhibitor) or LAT1-specific
siRNA treatment inhibits the uptake of L-leucine by human
primary T cells, as well as attenuating the immunological
functions of those T cells, such as the production of interferon-γ
(IFN-γ), IL-4 and IL-17.20 Although naive CD8+ T cells do not
effectively take up phenylalanine, activation of CD8+ T cells via
TCR triggering with a cognate peptide significantly increases
the transport of phenylalanine into those cells.11 Activated
CD8+ T cells from mice immunized with Listeria also show
enhanced phenylalanine uptake compared to naive T cells.11
Interestingly, activation CD8+ T cells increases the expression
of Slc3a2 and Slc7a5, and the abundance of LAT1 and CD98
proteins through calcineurin-regulated signaling pathways.11
Slc7a5-null CD4+ T cells do not respond to antigen receptor
ligation, and Slc7a5-null CD8+ T cells also have a severe defect
in their ability to respond to cognate antigen.11 Slc7a5-null OT-I
CD8+ T cells do not undergo a proliferative expansion after
antigen stimulation in vivo, indicating that Slc7a5 is essential for
the CD8 T-cell-mediated immune responses.11 Mechanically,
Slc7a5-null T cells are unable to activate mTORC1 signaling or
express c-Myc protein; thus, these T cells have reduced
glycolysis caused by a decrease in the expression of glucose
transporter-1 (Glut1), glucose uptake and lactate output and
decreased glutaminolysis caused by lowering glutamine and
arginine uptake.11
Activated T cells have higher rates of uptake of glutamine
(5–10-fold) compared with unstimulated T cells, and a defi-
ciency in glutamine impairs the late events in T-cell activation,
such as proliferation and cytokine secretion, although gluta-
mine depletion has no effect on the initiation of the activation of
T cells and their expression of T-cell surface markers CD69,
CD25 and CD98.44 Activation of T cells through CD3 and
CD28 induces the expression of the major glutamine
transporters (SNAT-1 and SNAT-2), and relocation of those
transporters from the cytoplasm to the cell surface.44 Activa-
tion of naive T cells with anti-CD3 plus anti-CD28 promotes a
rapid increase in the uptake of glutamine, and prolonged T-cell
activation further enhances the glutamine uptake, which is
largely dependent on ASCT2 because anti-CD3- and anti-
CD28-stimulated glutamine uptake is completely blocked in
ASCT2-deficient T cells.10 Mechanically, proximal signals
downstream of TCR and CD28 (CBM complex, composing of
CARMA1, BCL10 and MALT1) mediate glutamine uptake
induced by TCR and CD28 because a genetic deficiency in
either CARMA1, BCL10 or MALT1 severely attenuates the
anti-CD3 plus anti-CD28-induced glutamine uptake in T
cells.10 The loss of CARMA1 markedly inhibits TCR- and
CD28-stimulated ASCT2 mRNA expression, but has little
effect on the expression of other AA transporters, including
SNAT-1, SNAT-2, LAT1 and CD98.10 Also, CARMA1 physically
interacts with ASCT2, which is required for ASCT2 to
aggregate and colocalize rapidly with the TCR complex in
response to TCR and CD28 stimulation.10 However, Slc1a5+/+
and Slc1a5–/– T cells from young mice (6–7 weeks) display a
similar ability to proliferate and produce IL-2 after stimulation
by anti-CD3 and anti-CD28.10 Indeed, a deficiency in ASCT2
does not appreciably affect the TCR- and CD28-mediated
activation of transcription factors, including NF-κB, AP-1 and
nuclear factor of activated T cells, and the TCR- and CD28-
stimulated phosphorylation of signaling factors, including
mitogen-activated protein kinases, ERK, JNK and p38, IκB
kinase (IKK) and the IKK target IκBa.10 However, ASCT2 is
necessary for TCR- and CD28-mediated activation of
mTORC1 due to its effect on glutamine uptake.10
GAT-1 mRNA is detected in 50% of resting lymphocytes,
whereas GAT-2 mRNA is not detected in those cells, but all
activated lymphocytes express at least one of the two
transporters.17 Further study has demonstrated that protein
kinase C (PKC) has an important role in regulating GAT-1
expression by antigen-activated CD4+ T cells.9 Interestingly,
although T cells from Slc6a1−/− and WT mice have similar
levels of [3H]thymidine incorporation after Con A stimulation,
Slc6a1−/− CD4+ T cells have more robust incorporation of
[3H]thymidine after stimulation with anti-CD3 and anti-CD28
compared with WT CD4+ T cells.9 CD4+ T cells from Slc6a1−/−
mice also have higher IL-2 secretion and CD69 expression after
stimulation with anti-CD3 and anti-CD28 compared with those
cells from WT mice.9 GAT-1 negatively regulates CD4+ T-cell
cycle entry from G1 to S phase by inhibiting the expression of
G1–S phase proteins, such as cyclin A and CDK2, and by
promoting the expression of p21cip (an CDK inhibitor).9 GAT-1
deficiency interferes with apoptosis by enhancing the expres-
sion of antiapoptotic Bcl-2 family proteins.9 Mechanically, GAT-1
deficiency enhances the activity of PKCθ by regulating the
translocation and phosphorylation of PKCθ, leading to phos-
phorylation of JNK and activation of the NF-κB pathway to
promote cell survival and cell division.9
Collectively, LAT1 and ASCT2 are positively related to the
activation of T cells, whereas GATs are negatively associated
with T-cell activation. These results indicate that AA transpor-
ters have critical roles in the activation of T cells.
AA transporters and T-cell differentiation
The activated CD4+ T cells can differentiate into at least seven
distinct states under a specialized cytokine environment,
including Th1, Th2, Th9, Th17, Th22, Treg and T follicular
helper (Tfh) cells, each with a specific phenotypic and unique
functional characteristic (Figure 4). Th1 cells produce IL-2 and
IFN-γ,45 and requires the cytokine IL-12, the master transcrip-
tion factor TBX21 (T-box transcription factor) and the signaling
transducer and activator of transcription-4 (STAT4) for its
differentiation.46 Th2 cells produce IL-4, IL-5 and IL-13, as well
as IL-10.45,47 Available evidence shows that Th2 cell
differentiation depends on IL-4 and is controlled by GATA3
(trans-acting T-cell-specific transcription factor) and STAT6.48
Th9 cells preferentially produce IL-9.49,50,51 Differentiation
of Th9 cells and their release of IL-9 depend on IL-2, IL-4
and the transforming growth factor (TGF-β),52 and can be
enhanced by IL-1.49,50 IL-4 induced activation of STAT6 and
TGF-β-mediated activation of SMADs, such as SMAD2,
SMAD3 and SMAD4, are required for optimal differentiation
of Th9 cells.52 Th17 cells secrete IL-17A, IL-17F, IL-21 and
IL-22. TGF-β, IL-6, IL-1β and IL-23 promote Th17 cell differen-
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tiation through retinoic acid receptor-related orphan receptor-γt,
IFN-regulatory factor-4, aryl-hydrocarbon receptor (AHR) and
STAT3.53–56 Intriguingly, mTOR signaling also regulates Th17
cell differentiation and IL-17 gene expression.57–59 Th22 cells
produce IL-22, but not IL-17 or IFN-γ.60 The development of
Th22 cells from naive T cells requires stimulation of IL-6 and
tumor necrosis factor-α (TNF-α) or antigens in the context of
plasmacytoid dendritic cells, and depends on the AHR.45 Treg
cells produce IL-10 and TGF-β.45 TGF-β is required for the
generation of Tregs because TGF-β induces the expression of
Foxp3 and SMADs signaling.61,62 Tfh cells express CXCR5,
PD-1, ICOS, CD40L, Bcl-6 and IL-21.63 In mice, IL-6 and IL-21
have critical roles in the development of Tfh cells, whereas IL-12
participates in the early phase of development of Tfh cells.63,64
However, in humans, IL-12, IL-23 and TGF-β promote Tfh
development by increasing the expression of multiple transcrip-
tion factors in human naive CD4+ T cells, such as c-Maf and Batf,
which are essential for Tfh development.65–67
Slc7a5-null CD4+ T cells cannot normally differentiate into
Th1 or Th17 cells under the appropriate polarizing cytokines,
but they respond normally to TGF-β and IL-2 to differentiate into
Foxp3+ iTregs.11 Slc7a5fl/flCD4-Cre mice have a defect in
production of high-affinity IgG1 and affinity maturation of
antibody specific for T-cell-dependent antigen nitrophenyl-
OVA,11 indicating that Slc7a5 is also essential for the
differentiation of Tfh cells. Slc1a5–/– T cells have defects in
Th1 and Th17 cell differentiation, but not in differentiation of Th2
cells or Foxp3+ Treg cells.10 Transfer of Slc1a5–/– T cells to
Rag1–/–mice decreases IFN-γ+ Th1 cells, IL-17+ Th17 cells and
IFN-γ+ IL-17+ DPT cells, when compared with those transferred
with WT CD4+-naive T cells.10 Infection of the WT mice with
Listeria monocytogenes induces a population of antigen-
specific IFN-γ+ Th1 cells, whereas Slc1a5–/– mice have
profoundly reduced IFN-γ+ Th1 cells.10 Also, immunization of
Slc1a5+/+ mice with a myelin oligodendrocyte glycoprotein
peptide, along with injection with a pertussis toxin, leads to
severe experimental allergic encephalomyelitis (EAE) clinical
scores; however, the Slc1a5–/– mice have much milder clinical
EAE scores, and fewer IL-17-producing Th17 cells and IFN-γ-
producing Th1 cells in the central nervous system under the
same conditions.10 Mechanistically, the Slc1a5–/– T cell failure
to take up L-leucine leads to defects in mTORC1 signaling,
c-Myc expression, Glut1 expression, glucose uptake, lactate
secretion and glycolysis.10 Slc6a1−/− mice have a higher
expression of IFN-γ, TNF-α, IL-6, IL-23 and IL-17 mRNAs,
compared to the WT mice.16 Mechanistically, Slc6a1−/− mice
have a greater expression of T-bet, STAT1 and pSTAT1,
indicating that GAT-1 deficiency promotes the differentiation of
IFN-γ-producing Th1 cells.16
In summary, LAT1 and ASCT2 positively regulate the
differentiation of Th1 and Th17 cells, whereas GAT-1
negatively affects the differentiation of Th1 and Th17 cells.
These findings strongly indicate the significant roles of AA
transporters are in T-cell differentiation, especially for Th1 and
Th17 cells. These findings also suggest that modulation of AA
transporters could influence some T-cell-based immune
diseases, such as EAE, IBD and asthma.
AA transporters and T memory cells
Unlike activated or differentiated T cells, T memory (Tm) cells
survive longer and undergo intermittent cell division. Based on
Figure 4 Influence of the cytokine environment on the differentiation of T-helper (Th) cells. Once activated by stimulation from T-cell receptor (TCR) complex signaling, the
cytokine environment dictates Th cell differentiation. The prototypical cytokines and their corresponding signaling pathways that regulate the fate of each Th cell are depicted.
There are also additional cytokine and signaling pathways that can influence Th cells. In mice, the development of Tfh cells depends on IL-6 and IL-21, whereas IL-12 and TGF-β
signaling have critical roles in the development of Tfh cells in humans. LAT1 and ASCT2 are positively (+) associated with the differentiation of Th1 and Th17 cells, whereas GAT-1
is negatively (− ) associated with the differentiation of Th1 and Th17 cells
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homing and selectin molecule expression, effector cytokine
production and location, Tm cells are subdivided into: T central
memory cells, T effector memory cells, memory stem T cells,
T-residentmemory cells and follicular helper memory T cells.68
However, the homeostatic proliferation and survival of all
subsets are dependent on stimulation from IL-15 and
IL-7,69,70 and all subsets metabolize glucose, fatty acids and
AAs to generate ATP (Figure 1).4,71 There is increasing
evidence that the modulation of glucose metabolism or fatty
acid metabolism affects the fate of Tm cells.71–73 The trans-
portation of AAs by AA transporters or metabolism of AAsmay
also be critical in fate decisions of Tm cells. Interestingly,
inhibition of mTOR, raptor or FK506-binding protein 12 by
rapamycin treatment or RNA interference in antigen-specific
CD8+ T cells has immunostimulatory effects on the generation
of memory CD8+ T cells,74 which indicates that mTORC1
negatively the regulates CD8+ Tm cell fate decision, and that
AAs may also negatively regulate CD8+ Tm cell functions. The
percentage and number of memory CD4+ T cells are similar
between young (6–7 weeks) Slc1a5+/+ and Slc1a5–/– mice.10
However, Slc1a5 –/– with age of 5–6 months have a decreased
percentage and number of memory CD4+ T cells, with a
significant decrease in the population of CD44hiCD62Llo
memory T cells.10 Thus, AAs may influence Tm cell develop-
ment and longevity in some special physiological situations. It is
unknown whether AA metabolism has similar influences on
memory CD4+ T cells and memory CD8+ T cells. The influence
of AA metabolism or AA transportation on the fate decision of
Tm cells requires further investigation in pathogen-infected or
vaccine-immunized models.
Mechanism for AA transporters in shaping T-cell biology
As discussed above, current evidence strongly highlights the
importance of AA transporters in the activation of T cells, and
differentiation of Th1 and Th17 cells. However, the molecular
mechanism by which AA transporters regulate activation
and differentiation of T cells is unknown. One of the main
candidates is mTORC1 signaling, although other molecular
signaling pathways remain to be discovered. Through the
modulation of the cellular contents of AAs, AA transporters
regulate the activation of mTORC1 signaling, which has a
significant role in the activation of T cells, and differentiation of
Th1 and Th17 cells.75,76 For example, inhibition of mTORC1
signaling induces T-cell anergy even in the presence of signal
1 (TCR engagement) and 2 (costimulation).77 The inhibition of
mTORC1 by rapamycin in CD4 T cells decreases the
differentiation of Th1 and Th17 cells.37 The mTOR deficiency
in T cells inhibits the differentiation of Th1, Th2 or Th17 cells
from activated T cells.37 Deletion of RHEB in T cells inhibits the
Figure 5 Mechanism of L-leucine uptake by ASCT2 and LAT1 transporters. Polarized Na+ transported by a Na+/K+ ATPase pump provides power to ASCT2, a Na+-
dependent glutamine transporter, for cotransport of Na+ and glutamine. Concentrated glutamine is exchanged for L-leucine by an L-type AA transporter-1 (LAT1). L-leucine is an
important activator of the mechanic target of rapamycin complex 1 (mTORC1) signaling
Table 1 Effect of mouse-related amino-acid transporter deficiency in T-cell fate decision
T-cell
development
Naive T-cell
homeostasis
T-cell activation T-cell differentiation T-cell memory References
Slc7a5–/– mice No No T-cell activation↓ Th1 and Th17 cells↓ Not available 11
Slc1a5–/– mice No (1) For young micea:
No (2) For older miceb:
CD4+ T cells↓
CD44loCD62Lhi
CD4+ T cells↑
Activation of mTORC1
in T cellsc↓
Th1 and Th17 cells↓ (1) For young
micea: No
(2) For older
miceb: Memory
CD4+ T cells↓
10
Slc6a1–/– mice No No IL-2 secretion and
CD69 expression in
T cellsc ↑
Th1 cells↑ Not available 9,71
Abbreviations: IL, interleukin; mTORC1, mechanistic target of rapamycin complex 1; no, no effect; not available, the data are missing; Th, T-helper; ↑, increase; ↓,
decrease.
a6–7 weeks.
b5–6 months.
cAfter anti-CD3 and anti-CD28 stimulation.
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activation of mTORC1 signaling and differentiation of Th1 and
Th17 cells.78 The mTORC1 signaling regulates Th17 differ-
entiation through several pathways, including STAT3, hypoxia-
inducible factor-1α, ribosomal S6 kinase-1 (S6K-1) and
S6K2.79 Indeed, Slc7a5–/– T cells and Slc1a5–/– mice are
defective regarding the activation of mTORC1.10,11 Also, AA
transporters have been associated with autophagy,80,81 which
has remarkable effects on the development, maturation,
activation, differentiation and even memory of T cells;82,83
thus, the influence of AA transporters on the activation and
differentiation of T cells may be mediated via autophagy.
Conclusions
The cellular metabolism pathways highly shape the T-cell fate
decision, including T-cell development, homeostasis, activa-
tion, differentiation and memory. The regulation of glucose
metabolism and fatty acid oxidation in the fate decision of
T cells is widely highlighted.1,2,8 AA transporters are also
critical for the T-cell fate decision. This review has highlighted
compelling evidence that AA transporters affect peripheral
naive T-cell homeostasis, T-cell activation and differentiation,
especially for Th1 and Th17 cells, and T cell memory
(Figure 3). However, most investigations focus on LAT1 and
ASCT2, and GAT-1 perhaps because LAT1 and ASCT2 are
coupled with the transport of L-leucine (Figure 5),29 which is an
important activator of mTOR signaling,84 andGAT-1 transports
the GABA, a neurotransmitter. LAT1 and ASCT2 are positively
related to T-cell activation, as well as Th1 and Th17 cell
differentiation, whereas GAT-1 is negatively involved in the
activation and differentiation of T cells (Table 1). However, the
cellular and molecular mechanisms may be similar because L-
leucine activates mTORC1 signaling in the cytoplasm,84
whereas GABA activates mTORC1 signaling through GABA
receptors on the cell membrane (unpublished observation).
GAT-1 terminates GABA signaling by mediating the transloca-
tion of GABA from the extracellular space into the intracellular
space of cells. The mTORC1 signaling is of critical importance
to the activation and differentiation of T cells;59,85,86 thus, the
influence of AA transporters on the T-cell fate decision may
largely depend onmTORC1 signaling, although other possible
mechanisms remain to be known. It is also interesting to
explore the expression of other AA transporters in T cells and
regulation of the expressed AA transporters in the T-cell fate
decision. Furthermore, as most research is conducted using
conventional T cells, it will be of interest to uncover the
importance of AA transporters on unconventional T cells,
including CD1-restricted T cells, MR1-restricted mucosal-
associated invariant T cells, MHC class Ib-reactive T cells and
γδ T cells.87 We believe that understanding the influence of AA
transporters in T-cell fate determination offers significant
insights into T-cell-based immune diseases and opens up
novel potential treatments to prevent and cure T-cell-based
immune pathologies through modulation of the expression of
AA transporters and the metabolism of AA in T cells.
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